Press Releases
Nov. 29, 2021 Bioasis Announces Annual General Meeting Details
NEW HAVEN, Conn., Nov. 29, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™…
Oct. 28, 2021 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021
NEW HAVEN, Conn., Oct. 28, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
Sep. 30, 2021 Bioasis to Attend Upcoming Industry Conferences
NEW HAVEN, Conn., Sept. 30, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™…
Aug. 18, 2021 Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor
NEW HAVEN, Conn., Aug. 18, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
Aug. 9, 2021 Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion Protein Comprising Iduronate-2-sulfatase
NEW HAVEN, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
Jul. 29, 2021 Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A
NEW HAVEN, Conn., July 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),?a?pre-clinical, research-stage?biopharmaceutical company…
Jul. 20, 2021 Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager
NEW HAVEN, Conn., July 20, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
Jul. 7, 2021 Bioasis Announces Positive Results From an Efficacy Study of xB3™-IL-1RA in a Model of Multiple Sclerosis
NEW HAVEN, Conn., July 07, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
Jul. 1, 2021 Bioasis Announces the Appointment of Dave Jenkins as Chief Financial Officer
NEW HAVEN, Conn., July 01, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company…
Jun. 30, 2021 Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration
NEW HAVEN, Conn. and MANCHESTER, United Kingdom, June 30, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) (“Bioasis”) and Oxyrane UK Ltd. (“Oxyrane”) are pleased to…